Developments in the pharmacotherapeutic management of osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1603-1615

  Close, Pierre ^a   Neuprez, Audrey ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bisphosphonates; Cathepsin K; Denosumab; Fracture; Osteoporosis; Selective estrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; COLLAGEN; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN RECEPTOR; HUMAN MONOCLONAL ANTIBODY; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LASOFOXIFENE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; STRONTIUM RANELATE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE CANCER; BONE DENSITY; BONE MASS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS ULCER; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEADACHE; HIGH RISK PATIENT; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCALCEMIA; INCIDENCE; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; SPINE RADIOGRAPHY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CARRIER PROTEINS; CATHEPSINS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIP FRACTURES; HUMANS; MEMBRANE GLYCOPROTEINS; META-ANALYSIS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES; TERIPARATIDE; THIOPHENES;

EID: 33747041999     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1603     Document Type: Review

References (74)

1. CUMMINGS SR, BLACK DM, RUBIN SM: Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch. Intern. Med. (1989) 149:2445-2448.
2. REGINSTER JY, ABADIE E, DELMAS P et al.: Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos. Int. (2006) 17:1-7.
3. LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. (1995) 333:1437-1443.
4. BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535-1541.
5. CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082.
6. KARPF DB, SHAPIRO DR, SEEMAN E et al.: Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 277:1159-1164.
7. CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23:508-516.
8. BONE HG, HOSKING D, DEVOGELAER JP et al.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. (2004) 350:1189-1199.
9. DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. (1996) 335:1016-1021.
10. SCHNITZER T, BONE HG, CREPALDI G et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) (2000) 12:1-12.
11. HARRIS ST, WAITS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA (1999) 282:1344-1352.
12. REGINSTER JY, MINNE HW, SORENSEN OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. (2000) 11:83-91.
13. WATTS NB, JOSSE RG, HAMDY RC et al.: Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. (2003) 88:542-549.
14. SORENSEN OH, CRAWFORD GM, MULDER H et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 32:120-126.
15. BOONEN S, MCCLUNG M, EASTELL R, FULEIHAN G, BARTON I, DELMAS P: Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women 80 years of age or older: implications for the use of antiresorptive agents in the oldest old. J. Am. Geriatr. Soc. (2004) 52:1832-1839.
16. MCCLUNG MR, GEUSENS P, MILLER PD et al.: Hip Intervention Program Study Group: effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. (2001) 344:333-340.
17. CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23:517-523.
18. BROWN JP, KENDLER DL, MCCLUNG MR et al.: The efficacy and tolerability of risedronate once-a-week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. (2002) 71:103-111.
19. CHESNUT CH, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19:1241-1249.
20. REGINSTER JY, WILSON KM, DUMONT E, BONVOISIN B, BARRETT J: Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J. Clin. Endocrinol. Metab. (2005) 90:5018-5024.
21. REGINSTER JY, ADAMI S, LAKATOS P et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann. Rheum. Dis. (2006) 65(5):654-661.
22. EMKEY R, KOLTUN W, BEUSTERIEN K et al.: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, crossover trial: the Bonviva Alendronate trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. (2005) 21:1895-1903.
23. REGINSTER JY, RABENDA V, NEUPREZ A: Adherence, patient preference and dosing frequency: understanding the relationship. Bone (2006) 38:S2-S6.
24. REGINSTER JY: Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr. Pharm. Des. (2005) 11:3711-3728.
25. REID IR, BROWN JP, BURCKARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346:653-661.
26. POLASCIK TJ, GIVEN RW, METZGER C et al.: Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology (2005) 66:1054-1059.
27. BAMIAS A, KASTRITIS E, BAMIA C et al.: Osteoporosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. (2005) 23:8580-8587.
28. MARX RE, SAWATARI Y, FORTIN M, BROUMAND V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition. prevention, and treatment. J. Oral Maxillofac. Surg. (2005) 63:1567-1575.
29. RIGGS BL, HARTMANN LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. (2003) 348:618-629.
30. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351:1451-1467.
31. RYAN WG, WOLTER J, BAGDADE JD: Apparent beneficial effect of tamoxifen on bone mineral content in patients with breast cancer: preliminary study. Osteoporos. Int. (1991) 2:39-41.
32. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 282:637-645.
33. MARICIC M, ADACHI JD, SARKAR S, WU W, WONG M, HARPER KD: Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Intern. Med. (2002) 162:1140-1143.
34. DELMAS PD, GENANT HK, CRANS GG et al.: Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 33:522-532.
35. SIRIS E, ADACHI JD, LU Y et al.: Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Osteoporos. Int. (2002) 13:907-913.
36. KANIS JA, JOHNELL O, BLACK DM et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone (2003) 33:293-300.
37. DELMAS PD, ENSRUD KE, ADACHI JD et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. (2002) 87:3609-3617.
38. CUMMINGS SR, ECKERT S, KRUEGER KA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA (1999) 281:2189-2197.
39. MARTINO S, CAULEY JA, BARRETT-CONNOR E et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. (2004) 96:1751-1761.
40. REGINSTER JY, DEVOGELAER JP: Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin. Orthop. Rel. Res. (2006) 443:48-54.
41. KE HZ, FOLEY GL, SIMMONS HA, SHEN V, THOMPSON DD: Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology (2004) 145(4):1996-2005.
42. Lasofoxifene: CP 336156, CP-336156. Drugs RD (2005) 6(1):56-60.
43. SARKAR S, MITLAK BH, WONG M, STOCK JL, BLACK DM, HARPER KD: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. (2002) 17:1-10.
44. GENNARI L: Lasofoxifene (Pfizer). Curr. Opin. Investig. Drugs (2005) 6:1067-1078.
45. KOMM BS, KHARODE YP, BODINE PV, HARRIS HA, MILLER CP, LYTTLE CR: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 146:3999-4008.
46. GRUBER C, GRUBER D: Bazedoxifene (Wyeth). Curr. Opin. Investig. Drugs (2004) 5(10):1086-1093.
47. SATO M, TURNER CH, WANG T, ANDRIAN MD, ROWLEY E, BRYANT HU: LY35338LIICI: a novel raloxifene analog with improved SERM potency and efficacy in vivo. Pharmacol. Exp. Ther. (1998) 287:1-7.
48. MA YL, BRYANT HU, ZENG Q et al.: Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J. Bone Miner. Res. (2002) 17:2256-2264.
49. REGINSTER JY, TAQUET AN, FRAIKIN G, GOSSET C, ZEGELS B: Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos. Int. (1997) 7:S163-S167.
50. NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
51. MARCUS R, WANG O, SATTERWHITE J, MITLAK B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. (2003) 18:18-23.
52. LINDSAY R, SCHEELS WH, NEER R et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1-34)) in postmenopausal women with osteoporosis. Arch. Int. Med. (2004) 164:2024-2030.
53. PRINCE R, SIPOS A, HOSSAIN A et al.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. (2005) 20:1507-1513.
54. BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349:1207-1215.
55. KHOLSA S: Parathyroid hormone plus alendronate - a combination that does not add up. N. Engl. J. Med. (2003) 349:1277-1279.
56. RABENDA V, HANSSENS L, DE CEULAER F, REGINSTER JY: Is there any interest in combining treatments in osteoporosis? Curr. Rheum. Reviews (2005) 1:49-55.
57. JILKA RL, WEINSTEIN RS, BELLIDO T, ROBERSON P, PARFITT AM, MANOLAGAS SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. (1999) 104:371-373.
58. SHRADER SP, RAGGUCCI KR: Parathyroid hormone (1-84) and treatment of osteoporosis. Ann. Pharmacother. (2005) 39:1511-1516.
59. HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88:5212-5220.
60. HODSMAN AB, BAUER DC, DEMPSTER DW et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. (2005) 26:688-703.
61. MEUNIER PJ, SLOSMAN D, DELMAS P et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. (2002) 87:2060-2066.
62. REGINSTER JY, SPECTOR T, BADURSKI J et al.: A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The Strontium Ranelate Phase III Program. Osteoporos. Int. (2002) 13(S1):S30.
63. MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350:459-468.
64. REGINSTER JY, SEEMAN E, DE VERNEJOUL MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. (2005) 90:2816-2822.
65. HOFBAUER LC, SCHOPPET M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular disease. JAMA (2004) 292:490-495.
66. ABDALLAH BM, STILGREN LS, NISSEN N, KASSEM M, JORGENSEN HR, ABRAHAMSEN B: Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif. Tissue Int. (2005) 76:90-97.
67. BEKKER PJ, HOLLOWAY DL, RASMUSSEN AS et al.: A single-dose placebo-controlled study of MAG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. (2004) 19:1059-1066.
68. MCCLUNG MR, LEWIECKI EM, COHEN SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354:821-831.
69. YASUDA Y, KALETA J, BROMME D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. (2005) 57:973-993.
70. GRABOWSKAL U, CHAMBERS TJ, SHIROO M: Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Devel. (2005) 8:619-630.
71. BISKOBING DM: Novel therapies of osteoporosis. Expert Opin. Investig. Drugs (2003) 12(4):611-621.
72. LARK MW, STROUP GB, JAMES IE et al.: A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone (2002) 30:746-753.
73. STROUP GB, LARK MW, VEBER DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo nonhuman primate. J. Bone Miner. Res. (2001) 16:1739-1746.
74. BOONEN S, BODY JJ, BOUTSEN Y et al.: Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. (2005) 16:239-254.